CWP
ABBV icon

CFM Wealth Partners’s AbbVie ABBV Stock Holding History

CFM Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.6M Sell
26,216
-307
-1% -$66K 0.84% 30
2026
Q1 		$5.77M Buy
26,523
+480
+2% +$106K 0.86% 31
2025
Q4 		$5.95M Buy
26,043
+1,635
+7% +$372K 0.86% 32
2025
Q3 		$5.65M Buy
24,408
+1,394
+6% +$284K 0.82% 34
2025
Q2 		$4.27M Buy
23,014
+415
+2% +$77.1K 0.68% 41
2025
Q1 		$4.74M Buy
22,599
+644
+3% +$125K 0.84% 36
2024
Q4 		$3.9M Buy
21,955
+752
+4% +$138K 0.66% 41
2024
Q3 		$4.19M Buy
21,203
+78
+0.4% +$14.6K 0.73% 36
2024
Q2 		$3.62M Buy
21,125
+861
+4% +$143K 0.67% 37
2024
Q1 		$3.69M Buy
20,264
+961
+5% +$166K 0.74% 35
2023
Q4 		$2.99M Buy
19,303
+103
+0.5% +$15K 0.68% 41
2023
Q3 		$2.86M Buy
19,200
+425
+2% +$62.4K 0.75% 39
2023
Q2 		$2.53M Sell
18,775
-78
-0.4% -$11.4K 0.61% 46
2023
Q1 		$3M Buy
18,853
+367
+2% +$56.1K 0.81% 36
2022
Q4 		$2.99M Buy
18,486
+91
+0.5% +$14K 0.89% 34
2022
Q3 		$2.47M Buy
18,395
+2,687
+17% +$386K 0.79% 36
2022
Q2 		$2.41M Buy
15,708
+434
+3% +$66.3K 0.72% 36
2022
Q1 		$2.48M Sell
15,274
-246
-2% -$35.7K 0.59% 46
2021
Q4 		$2.1M Hold
15,520
– – 0.47% 54
2021
Q3 		$1.67M Buy
15,520
+257
+2% +$29.4K 0.42% 55
2021
Q2 		$1.72M Buy
15,263
+526
+4% +$59.2K 0.46% 51
2021
Q1 		$1.59M Buy
14,737
+361
+3% +$38.6K 0.48% 50
2020
Q4 		$1.54M Buy
14,376
+234
+2% +$22.5K 0.49% 51
2020
Q3 		$1.24M Buy
14,142
+1,077
+8% +$101K 0.45% 48
2020
Q2 		$1.28M Buy
13,065
+786
+6% +$69.2K 0.49% 47
2020
Q1 		$936K Buy
12,279
+652
+6% +$55.5K 0.43% 50
2019
Q4 		$1.04M Buy
+11,627
New +$965K 0.38% 57

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CFM Wealth Partners's ABBV Position: Q2 2026 in Review

CFM Wealth Partners reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $66K and leaving 26,216 shares worth $6.6M. The position accounts for 0.84% of the portfolio, ranked #30.

CFM Wealth Partners first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • CFM Wealth Partners held 26,216 shares of AbbVie worth $6.6M as of Q2 2026.
  • CFM Wealth Partners sold 307 AbbVie shares in Q2 2026, an estimated $66K.
  • AbbVie made up 0.84% of CFM Wealth Partners's portfolio in Q2 2026, its #30 holding.
  • CFM Wealth Partners first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CFM Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.